UnitedHealth Group has remained a subject of active institutional attention through mid-2026. The company operates across managed care, pharmacy benefits, and health services segments, and has drawn continued scrutiny amid a broader environment of elevated healthcare costs and ongoing regulatory developments. Prior briefings published on 2026-06-09, 2026-06-17, and 2026-06-25 each noted sustained institutional focus on the name across successive reporting periods [Brief - 2026-06-25] [Brief - 2026-06-17] [Brief - 2026-06-09].
As of the quarter ending 2026-03-31, UnitedHealth Group reported trailing twelve-month revenue of approximately $449.7 billion, reflecting year-over-year growth of 1.96%. Net income on a TTM basis stood at $12.8 billion, with a net margin of 2.85% and an operating margin of 4.19%. EPS growth on a year-over-year basis was 0.73%. The company held $28.0 billion in cash against total debt of $77.9 billion. The reported P/E ratio was 32.03, with a market capitalisation of approximately $386.2 billion [SEC 10-Q - UNH - 2026-03-31].
Insider activity over the past 30 days recorded 17 transactions with a mixed directional profile and a net value of zero, indicating no material net accumulation or disposal among insiders [SEC Form 4 - UNH - 2026-07]. At the institutional level, Millennium Management added 56% to its position and AQR Capital added 36%, while Citadel reduced its position by 19% and Tiger Global reduced by 17%. Soros Fund Management added 14% to its holding. These divergent movements across major institutional filers represent the primary trigger for this report [SEC 13F - Millennium - Q1 2026] [SEC 13F - AQR Capital - Q1 2026] [SEC 13F - Citadel - Q1 2026] [SEC 13F - Tiger Global - Q1 2026] [SEC 13F - Soros Fund Mgmt - Q1 2026].
The 10-year US Treasury yield stood at 4.48% and the 2-year at 4.17% as of the report date, reflecting a normal yield curve configuration. This rate environment is relevant context for large-cap healthcare companies carrying substantial debt loads, as borrowing costs and discount rates factor into financial planning and valuation frameworks across the sector [FRED DGS10] [FRED DGS2].